Mobile

An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001718-15

An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participated in previous Roche or Roche partner protocols

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To provide treatment or re-treatment to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche partner protocol where access to treatment or re-treatment with PEGASYS as monotherapy or in combination with COPEGUS was promised or deemed appropriate following completion of the original protocol (‘donor’ protocol).

Critère d'inclusion

  • Chronic hepatitis C

Liens